Pinnacle Biologics Acquires PDT Laser Tech
Pinnacle Biologics Inc. has completed its portfolio of photodynamic therapy (PDT) treatment components with the acquisition of Diomed’s PDT 630 laser and fiber optic diffuser Optiguide. Financial terms were not disclosed.
The privately-held biopharmaceutical company’s acquisitions are the only FDA-approved devices for use in PDT with Photofrin (porfimer sodium) for injection.
Photofrin — acquired by the company in March 2011 — is a two-stage process requiring administration of both drug and light. When injected, it is attracted to certain tissues, especially cancer cells, and is FDA-approved for the treatment of nonsmall-cell lung and esophageal cancer.
For more information, visit:
www.pinnaclebiologics.com
LATEST NEWS
- Fusion Startup Xcimer Raises $100M, Plans Laser Prototype
Jun 4, 2024
- ASML and imec Debut Joint Lithography Lab
Jun 4, 2024
- Photonic and Microsoft Detail Quantum Computing Milestone
Jun 4, 2024
- LOPS 2024 Conference to Showcase Latest Innovations
Jun 4, 2024
- Coherent Names CEO
Jun 3, 2024
- CEA-Leti Reports Progress on AI-Embedded CMOS Image Sensors
Jun 3, 2024
- Obsidian Sensors Partners, Secures Investment to Advance Thermal Image Sensor Tech
Jun 3, 2024
- Hamamatsu Completes Acquisition of NKT Photonics
May 31, 2024